Anil K Singh1, Sadiq Umar1, Sharayah Riegsecker2, Mukesh Chourasia3, Salahuddin Ahmed1. 1. Washington State University College of Pharmacy, Spokane. 2. University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, Ohio. 3. National Institute of Pharmaceutical Education and Research, Hajipur, India.
Abstract
OBJECTIVE: Transforming growth factor β-activated kinase 1 (TAK1) is a key MAPKKK family protein in interleukin-1β (IL-1β), tumor necrosis factor (TNF), and Toll-like receptor signaling. This study was undertaken to examine the posttranslational modification of TAK1 and its therapeutic regulation in rheumatoid arthritis (RA). METHODS: The effect of TAK1, IL-1 receptor-associated kinase 1 (IRAK-1), and TNF receptor-associated factor 6 (TRAF6) inhibition was evaluated in IL-1β-stimulated human RA synovial fibroblasts (RASFs). Western blotting, immunoprecipitation, and 20S proteasome assay were used to study the ubiquitination process in RASFs. The efficacy of epigallocatechin-3-gallate (EGCG), a potent antiinflammatory molecule, in regulating these processes in RASFs was evaluated. Molecular docking was performed to examine the interaction of EGCG with human TAK1, IRAK-1, and TRAF6. These findings were confirmed using a rat model of adjuvant-induced arthritis (AIA). RESULTS: Inhibition of TAK1, but not IRAK-1 or TRAF6, completely abrogated IL-1β-induced IL-6 and IL-8 synthesis in RASFs. EGCG inhibited TAK1 phosphorylation at Thr(184/187) and occupied the C(174) position, an ATP-binding site, to inhibit its kinase activity. EGCG pretreatment also inhibited K(63) -linked autoubiquitination of TRAF6, a posttranslational modification essential for TAK1 autophosphorylation, by forming a stable H bond at the K(124) position on TRAF6. Furthermore, EGCG enhanced proteasome-associated deubiquitinase expression to rescue proteins from proteasomal degradation. Western blot analyses of joint homogenates from rats with AIA showed a significant increase in K(48) -linked polyubiquitination, TAK1 phosphorylation, and TRAF6 expression when compared to naive rats. Administration of EGCG (50 mg/kg/day) for 10 days ameliorated AIA in rats by reducing TAK1 phosphorylation and K(48) -linked polyubiquitination. CONCLUSION: Our findings provide a rationale for targeting TAK1 for the treatment of RA with EGCG.
OBJECTIVE: Transforming growth factor β-activated kinase 1 (TAK1) is a key MAPKKK family protein in interleukin-1β (IL-1β), tumor necrosis factor (TNF), and Toll-like receptor signaling. This study was undertaken to examine the posttranslational modification of TAK1 and its therapeutic regulation in rheumatoid arthritis (RA). METHODS: The effect of TAK1, IL-1 receptor-associated kinase 1 (IRAK-1), and TNF receptor-associated factor 6 (TRAF6) inhibition was evaluated in IL-1β-stimulated humanRA synovial fibroblasts (RASFs). Western blotting, immunoprecipitation, and 20S proteasome assay were used to study the ubiquitination process in RASFs. The efficacy of epigallocatechin-3-gallate (EGCG), a potent antiinflammatory molecule, in regulating these processes in RASFs was evaluated. Molecular docking was performed to examine the interaction of EGCG with humanTAK1, IRAK-1, and TRAF6. These findings were confirmed using a rat model of adjuvant-induced arthritis (AIA). RESULTS: Inhibition of TAK1, but not IRAK-1 or TRAF6, completely abrogated IL-1β-induced IL-6 and IL-8 synthesis in RASFs. EGCG inhibited TAK1 phosphorylation at Thr(184/187) and occupied the C(174) position, an ATP-binding site, to inhibit its kinase activity. EGCG pretreatment also inhibited K(63) -linked autoubiquitination of TRAF6, a posttranslational modification essential for TAK1 autophosphorylation, by forming a stable H bond at the K(124) position on TRAF6. Furthermore, EGCG enhanced proteasome-associated deubiquitinase expression to rescue proteins from proteasomal degradation. Western blot analyses of joint homogenates from rats with AIA showed a significant increase in K(48) -linked polyubiquitination, TAK1 phosphorylation, and TRAF6 expression when compared to naive rats. Administration of EGCG (50 mg/kg/day) for 10 days ameliorated AIA in rats by reducing TAK1 phosphorylation and K(48) -linked polyubiquitination. CONCLUSION: Our findings provide a rationale for targeting TAK1 for the treatment of RA with EGCG.
Authors: Yanhong Cao; Yan Jiao; Lishi Wang; Yue Huang; Arnold Postlethwaite; John Stuart; Andy Kang; Robert W Williams; Weikuan Gu Journal: Int Immunopharmacol Date: 2012-03-14 Impact factor: 4.932
Authors: Yang Yu; Ningling Ge; Min Xie; Wenjing Sun; Susan Burlingame; Amy K Pass; Jed G Nuchtern; Dekai Zhang; Songbin Fu; Michael D Schneider; Jia Fan; Jianhua Yang Journal: J Biol Chem Date: 2008-07-10 Impact factor: 5.157
Authors: Juliane Totzke; Deepak Gurbani; Rene Raphemot; Philip F Hughes; Khaldon Bodoor; David A Carlson; David R Loiselle; Asim K Bera; Liesl S Eibschutz; Marisha M Perkins; Amber L Eubanks; Phillip L Campbell; David A Fox; Kenneth D Westover; Timothy A J Haystead; Emily R Derbyshire Journal: Cell Chem Biol Date: 2017-08-17 Impact factor: 8.116
Authors: Nikolay N Kuzmich; Konstantin V Sivak; Vladimir N Chubarev; Yuri B Porozov; Tatiana N Savateeva-Lyubimova; Francesco Peri Journal: Vaccines (Basel) Date: 2017-10-04